Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flupentixol-Melitracen + Lansoprazole for Functional Dyspepsia
NCT06931223Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Apr 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of flupentixol + melitracen in functional dyspepsia (FD) (2 arms), sponsored by Renji Hospital. Primary endpoint: Leuven Postprandial Distress Scale at 14 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
flupentixol + melitracen
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on NCT06931223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06931223.